Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

Share Price is delayed by 15 minutes
Get Live Data
103.20    -5.80 (-5.32%)
Bid:
103.00
Ask:
104.20
Spread: 1.20 (1.165%)
Market Cap: £169.19m
SYNT Live PriceLast checked at - London Stock Exchange

Intraday Synthomer Share Chart

Q3 Trading update

6 Nov 2018 07:00

RNS Number : 4119G
Synthomer PLC
06 November 2018
 

November 6th 2018

Synthomer plc

Q3 Trading update

Solid Q3 performance; Full Year 2018 outlook unchanged

Synthomer plc ('Synthomer' or 'the Group') today issues a trading update for the third quarter ('Q3') ended September 30th 2018.

Trading

Europe and North America:

Europe and North America reported a solid quarter's results. Excluding sales volumes associated with Pischelsdorf, which was acquired in February 2018, volumes were slightly lower than the comparative Q3 period. Unit margins, excluding Pischelsdorf, were slightly above Q3 2017, with all segments apart from Paper showing a positive movement reflecting the benefits of further investment and increased efficiencies across the business.

Asia and Rest of World:

Asia and Rest of World continued to grow in line with our expectations. Nitrile Latex volumes were slightly ahead of a strong comparative period in Q3 2017. Nitrile Latex unit margins were also higher than the comparative period and in line with unit margins in H1 2018.

The expansion of our Pasir Gudang Nitrile Latex plant was successfully commissioned on time during September 2018. The plant will produce saleable products for customers and make a small contribution to the Group in Q4. Demand for Nitrile Latex remains robust and we have initiated our preliminary work for a further 60kt expansion at Pasir Gudang during 2020.

Financial Position

At September 30th, the Group had net debt of £256m (Q3 2017: £232m), with the increase since June 30th reflecting the planned step up in capital expenditure in H2 2018 (£20m), further investment in working capital (£40m) and the 2017 final dividend (£29m). Going forward, working capital is expected to remain at circa 10% of sales.

FY 2018 Outlook Unchanged

Synthomer's product and geographic diversity means that we are well positioned to withstand the challenging macroeconomic and political environment and, along with the good performance in the first 9 months of the year, the Board's expectations for Full Year 2018 remain unchanged.

Organisational Structure Change

In order to accelerate sales growth, sharpen our commercial focus and drive operational efficiencies, the Group will be reorganised from January 2019. Three new business groups will be created: Performance Elastomers (Styrene Butadiene Rubber and Nitrile Butadiene Latex), Functional Solutions (Dispersions) and Specialities.

The new structure will enable Synthomer to better leverage its global product portfolio and customer relationships, better exploit its R&D capability within chemistries, and bring greater operational focus to production sites.

The new structure combines sales, marketing, research and production by business group into dedicated global teams whilst retaining very strong regional strength and local focus. The Group will report FY 2018 numbers under the existing geographic reporting structure and at the same time publish certain segmental information under the new structure, which will then be adopted on a permanent basis going forward.

ENDS

 

Enquiries:

Calum MacLean, Chief Executive Officer

+44 1279 436 211

Stephen Bennett, Chief Financial Officer

 

Charles Armitstead, Teneo

+44 203 603 5220

 

The Company will hold a conference call for investors and analysts at 0800 GMT today.

Please dial +44 3333000804 entering conference ID: 31828488# to gain access to the call.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTUVOKRWRAARAA
Date   Source Headline
1st Jun 20262:42 pmRNSHolding(s) in Company
29th May 20263:57 pmRNSTotal Voting Rights
22nd May 20265:21 pmRNSNotice of AGM
8th May 20264:33 pmRNSAdmission to Trading
7th May 20261:51 pmRNSApplication for Admission to Trading
5th May 20264:25 pmRNSHolding(s) in Company
30th Apr 20264:40 pmRNSAnnual Financial Report
30th Apr 20263:17 pmRNSDirector/PDMR Shareholding
30th Apr 202611:25 amRNSDirector/PDMR Shareholding
30th Apr 20267:01 amRNSChange of Chief Financial Officer
30th Apr 20267:00 amRNSFinal Results
19th Mar 20267:00 amRNSTrading and refinancing update
11th Feb 20261:46 pmRNSStatement re potential refinancing
29th Jan 20267:00 amRNSTrading Statement - Winter 2026
27th Jan 20264:51 pmRNSHolding(s) in Company
26th Jan 20264:23 pmRNSHolding(s) in Company
18th Dec 20257:00 amRNSReceivables purchasing arrangement
12th Dec 20259:30 amRNSDirectorate change
12th Nov 20257:00 amRNSDirector/PDMR Shareholding
5th Nov 20251:28 pmRNSHolding(s) in Company
23rd Oct 20257:00 amRNSTrading statement - Autumn 2025
14th Oct 20257:00 amRNSAppointment of joint corporate broker
4th Sep 20255:17 pmRNSHolding(s) in Company
11th Aug 20258:00 amRNSDirector/PDMR Shareholding
6th Aug 20259:45 amRNSDirector/PDMR Shareholding
5th Aug 202511:57 amRNSDirector/PDMR Shareholding
5th Aug 202511:00 amRNSDirectorate Change
5th Aug 20257:00 amRNSInterim results
4th Jul 20257:01 amRNSDirector/PDMR Shareholding
1st Jul 20257:00 amRNSCovenant update
30th Jun 20257:00 amRNSDirectorate Changes
27th Jun 20254:21 pmRNSHolding(s) in Company
2nd Jun 20257:00 amRNSDivestment of William Blythe completed
6th May 20257:00 amRNSDivestment of William Blythe
1st May 20254:18 pmRNSResults of AGM
1st May 20257:00 amRNSTrading Statement - Spring 2025
15th Apr 20253:00 pmRNSHolding(s) in Company
28th Mar 20257:30 amRNSDirector/PDMR Shareholding
27th Mar 20257:30 amRNSDirector/PDMR Shareholding
25th Mar 20254:23 pmRNSAnnual Report and Notice of AGM
25th Mar 202511:43 amRNSDirector/PDMR Shareholding
25th Mar 202511:41 amRNSDirector/PDMR Shareholding
24th Mar 20257:30 amRNSHolding(s) in Company
17th Mar 20259:00 amRNSDirector/PDMR Shareholding
17th Mar 20259:00 amRNSDirector/PDMR Shareholding
11th Mar 20257:00 amRNSFinal Results
6th Mar 20258:32 amRNSDirector Declaration
13th Feb 20257:00 amRNSHolding(s) in Company
28th Jan 202510:30 amRNSDirector/PDMR Shareholding
28th Jan 20257:00 amRNSWinter trading statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.